Research Comparison

Retatrutide (GLP-3) vs Semaglutide

Retatrutide (GLP-3) and Semaglutide are often compared because both sit in metabolic research. Retatrutide (GLP-3) acts on GLP-1 + GIP + glucagon (triple agonist) and is studied for metabolic & body-weight research, while Semaglutide acts on GLP-1 (mono agonist) and is studied for metabolic & body-weight research. Both are supplied as lyophilized powder for in-vitro laboratory research only — this page compares mechanism and research status, not dosing or human use.

Retatrutide (GLP-3)

Metabolic

Semaglutide

Metabolic

Category
Metabolic
Metabolic
Mechanism / target
GLP-1 + GIP + glucagon (triple agonist)
GLP-1 (mono agonist)
Research status
Phase 3 (investigational)
Approved formulations exist
Studied for
Metabolic & body-weight research
Metabolic & body-weight research
Form
Lyophilized powder
Lyophilized powder

Retatrutide (GLP-3)

Metabolic & body-weight research.

Semaglutide

Metabolic & body-weight research.

Frequently asked

What is the difference between Retatrutide (GLP-3) and Semaglutide?
The main difference is mechanism and research stage. Retatrutide (GLP-3) targets GLP-1 + GIP + glucagon (triple agonist) (phase 3 (investigational)) and is studied for metabolic & body-weight research; Semaglutide targets GLP-1 (mono agonist) (approved formulations exist) and is studied for metabolic & body-weight research. Both are research-use-only compounds, not for human or animal use.
Are Retatrutide (GLP-3) and Semaglutide approved for human use?
No. Renova Wellness supplies both strictly for in-vitro laboratory and scientific research use only. Research status differs — Retatrutide (GLP-3): phase 3 (investigational); Semaglutide: approved formulations exist — but neither is sold for human or animal consumption, and no medical, therapeutic, or dosing claims are made.
How is purity verified for Retatrutide (GLP-3) and Semaglutide?
Every lot of both compounds ships with its own per-batch Certificate of Analysis — identity by mass spectrometry, ≥98% purity by HPLC, and a unique lot number you can verify against the vial in your hand.

Related comparisons

Build a multi-compound set in the Stack Builder or run the reconstitution calculator.

Research references

Primary literature for Retatrutide (GLP-3) and Semaglutide. Provided for scientific context only — not medical or dosing guidance.

  1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315
  2. Rosenstock J, et al. Retatrutide for people with type 2 diabetes: a randomised phase 2 trial. Lancet. 2023. PMID 37385280
  3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID 33567185
  4. Amaro A, et al. Cardiometabolic risk factors efficacy of semaglutide in the STEP program. Postgrad Med. 2022. PMID 36691308

Research use only. This comparison covers mechanism, target, and research status. It is not medical, therapeutic, or dosing advice. Compounds sold by Renova Wellness™ are for in-vitro laboratory research and are not for human or animal consumption.